Themes US Cash Flow Champions ETF (NASDAQ: LGCF)

Dernières nouvelles pour Themes US Cash Flow Champions ETF (NASDAQ:LGCF)

Financial Services

Energy

Healthcare

Technology

Consumer Defensive

Consumer Cyclical

Basic Materials

Communication Services

Industrials

To pursue its objective, the fund employs a passive management (or indexing) investment approach designed to track the performance, before fees and expenses, of the Solactive US Cash Flow Champions Index, or any successor thereto (the Index). The Index is based on a proprietary methodology developed and maintained by Solactive AG (the Index Provider), which is an organization that is independent of, and unaffiliated with, the Fund and Themes Management Company, LLC, the Funds investment adviser (the Adviser).

Broadcom Inc

Exxon Mobil Corp.

Jpmorgan Chase & Co.

Chevron Corp.

Abbvie Inc.

Pfizer, Inc.

American Express Co.

Conocophillips Co

Progressive Corp.

Regeneron Pharmaceuticals, Inc.

Wells Fargo & Co.

Uber Technologies Inc

Gilead Sciences Inc

Themes US Cash Flow Champions ETF

Lavras Gold Corp

<p><strong>Roche Holdings AG</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced on Tuesday that it will invest $50 billion in the U.S. over <a href="https://www.benzinga.com/topic/pharmaceuticals">the next five years.</a></p>
<p>These investments further strengthen Roche's already significant U.S. footprint, which includes 13 manufacturing and 15 R&amp;D sites across the Pharmaceutical and Diagnostics Divisions.</p>
<p>The investment is expected to <a href="https://www.roche.com/media/releases/med-cor-2025-04-22" target="_blank" rel="noreferrer noopener">create</a> over 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 jobs at new and expanded facilities.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a></strong></p>
<p>As part of this investment, Roche will increase its footprint of more than 25,000 employees in 24 sites across eight U.S. states. The investment will include: </p>
<ul>
<li>Expanded and upgraded US manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon, and California.</li>
<li>Gene therapy manufacturing facility in Pennsylvania.</li>
<li>A new 900,000-square-foot manufacturing center to support Roche's expanding portfolio of <a href="https://www.benzinga.com/general/biotech/25/04/44791986/whats-going-on-with-viking-therapeutics-structure-therapeutics-stock-on-monday" target="_blank" rel="noreferrer noopener">next-generation weight loss medicines</a>. The company says the location will be announced.</li>
<li>A new manufacturing facility for continuous glucose monitoring in Indiana.</li>
<li>A new R&amp;D center in Massachusetts for conducting artificial intelligence research and as a hub for new cardiovascular, renal, and metabolism R&amp;D efforts.</li>
<li>Significant expansion and upgrading of existing pharmaceuticals and diagnostics R&amp;D centers in Arizona, Indiana, and California.</li>
</ul>
<p>Once all new and expanded manufacturing capacity comes online, Roche will export more medicines from the U.S. than it imports. The company says its diagnostics division already has an export surplus from the U.S. to other countries.</p>
<p>Earlier this month, <strong>Novartis AG </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertainties" target="_blank" rel="noreferrer noopener">over the next five years</a>.</p>
<p>The move is part of a broader strategy to ensure that all key Novartis medicines for U.S. patients are produced domestically.</p>
<p>Earlier this year, <strong>Johnson &amp; Johnson</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced its plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>, while <strong>Eli Lilly And Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) plans to double its U.S. drug manufacturing spending from $23 billion to <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">$50 billion within five years</a>.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/asset-sales/25/04/44929060/boeing-finalizes-10-55-billion-deal-to-divest-jeppesen-and-foreflight-assets" target="_blank" rel="noreferrer noopener">Boeing Finalizes $10.55 Billion Deal To Divest Jeppesen And ForeFlight Assets</a></strong></li>
</ul>
<p><em>Photo: Gorodenkoff/Shutterstock</em></p>


Biotech

Large Cap

News

Health Care

General

RHHBY

Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs

<p><strong>On Tuesday, Sapiens International Corporation </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) disclosed its plan to acquire <strong>Candela </strong>for an aggregate <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44915217/sapiens-acquires-candela-to-expand-its-footprint-in-apac-and-enhance-its-life-product-portfolio" rel="noreferrer noopener">cash consideration of&nbsp;$22 million</a>.</p>
<p>Candela offers an end-to-end insurance automation platform along with digital services and solutions in the APAC region.</p>
<p>The acquisition is intended to strengthen Sapiens' life insurance offerings and broaden its footprint across Asia-Pacific.</p>
<p>The deal is anticipated to close in the second quarter of 2025, pending regulatory approvals and closing conditions.</p>
<p>Candela's offerings complement Sapiens' Insurance Platform and Life Policy Administration Systems.</p>
<p>By integrating Candela's strengths in Business Process Modelling (BPM) and Case Management, Sapiens plans to enhance its life insurance solutions.</p>
<p>The acquisition will also allow for the integration of standardized workflows across third-party legacy systems, delivering a more streamlined and consistent experience for agents, customers, and administrators.</p>
<p>Roni Al-Dor, CEO and President at Sapiens, said, "We will continue to support Candela's customers and products, increasing value across the entire insurance lifecycle and supporting insurers' digital transformations with a comprehensive product proposition and a diverse range of service capabilities."</p>
<p>Amitabh Poddar, Business Head at Candela, added, "Integrating our intelligent automation solutions into Sapiens' leading insurance software platform will enhance our capabilities and provide even greater value to our customers."</p>
<p>Notably, Candela reported non-GAAP revenues of $8 million for the full year 2024. The transaction is expected to be accretive to Sapiens' profitability <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">beginning in the fourth quarter of 2025</a>.</p>
<p>The deal is expected in the second quarter of 2025 and Candela will operate as a wholly owned subsidiary of Sapiens.</p>
<p>The company disclosed the first quarter of<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener"> 2025 results on May 8, 2025</a>.</p>
<p>As of December 31, cash and cash <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43775499/sapiens-reports-fourth-quarter-2024-financial-results" rel="noreferrer noopener">equivalent stood at $163.7 million</a>.</p>
<p>Investors can gain exposure to the stock via <strong>ARK Israel Innovative Technology ETF</strong> (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IZRL#BATS">IZRL</a>).</p>
<p><strong>Price Action</strong>: SPNS shares are up 3.30% at $26.28 at the last check on Tuesday.</p>
<p><strong>Read Next</strong>:</p>
<ul>
<li><strong><em><a href="https://www.benzinga.com/tech/25/04/44911125/dan-loebs-bet-on-taiwan-semiconductor-looks-strong-as-q1-results-top-expectations" target="_blank" rel="noreferrer noopener">Dan Loeb's Bet On Taiwan Semiconductor Looks Strong As Q1 Results Top Expectations</a></em></strong></li>
</ul>
<p><em>Photo via Shutterstock</em></p>


Equities

Small Cap

IZRL

SPNS

Sapiens Taps APAC Growth With $22 Million Candela Acquisition

WIIM

Shares of retail and consumer discretionary stocks are trading higher following US Treasury Secretary Scott Bessent's reported remarks about trade de-escalation with China. De-escalation with China could reduce supply chain uncertainty and boost consumer sentiment.

<p>Cantor Fitzgerald initiated coverage on <strong>Eli Lilly And Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Monday, citing orforglipron data, which strengthens <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">the case for obesity dominance</a>.</p>
<p>Last week, the U.S. drug giant reported topline Phase 3 results from the ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with <a href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" target="_blank" rel="noreferrer noopener">diet and exercise alone</a>.</p>
<p>In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C (blood sugar) reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential" rel="noreferrer noopener">using the efficacy estimand</a>.</p>
<p>After a choppy second half of 2024, &#8220;Lilly is off to a solid start in &#8217;25,&#8221; Cantor analyst Carter Gould writes. The company reported positive orforglipron ACHIEVE-1 data and improved underlying GLP-1 commercial metrics. </p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44907170/upcoming-pfizer-earnings-call-might-be-focused-on-tariffs-policy-risks-and-obesity-pipeline" rel="noreferrer noopener">Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline</a></strong></p>
<p>&#8220;&#8230;We view the ACHIEVE-1 data as meaningfully de-risking a 13-16% weight loss profile, and if safety/tolerability holds up, it should leave LLY well-positioned to take share from semaglutide and further grow the market with an oral approach,&#8221; analyst Gould adds.</p>
<p>Cantor writes that Eli Lilly could have an over 85% share of the obesity market by 2029-2030E when the next wave of entrants hits. Cantor initiated with an Overweight rating and a <a target="_blank" href="https://www.benzinga.com/quote/LLY/analyst-ratings" rel="noreferrer noopener">price target of $975</a>.</p>
<p>Eli Lilly&#8217;s first-quarter earnings are in the front row for investors.</p>
<p>The company is scheduled to release the financial performance on 1 May. Analysts expect $4.79 per share earnings with <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $12.93 billion</a>.</p>
<p>Cantor expects modest beats across Mounjaro/Zepbound and that the company will likely reaffirm the FY25 topline guide ($59-61 billion) as a raise is more likely after the second quarter of 2025.</p>
<p>In March, the company announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in India, which is expected to have the second-largest population of overweight or&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44824190/eli-lillys-mounjaro-launch-triggers-weight-loss-craze-in-india-novo-nordisk-seeks-to-move-up-wegovy-launch" rel="noreferrer noopener">obese people by 2050</a>.</p>
<p>Rival<strong>&nbsp;Novo Nordisk A/S&#8217;&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is feeling the pressure as it tries to move up the launch of Wegovy in India to better compete with Lilly.</p>
<p>BofA Securities has also made minor changes to its model for Eli Lilly ahead of Q1 earnings.</p>
<p>BofA analyst Tim Anderson writes that IQVIA recently began including Lilly Direct vials in its TRx (total prescription) data. As for pricing, Eli Lilly expects an overall price decline by the mid-to-high single digits in 2025. While this isn&#8217;t specific to any product, the company suggests that falling prices for its obesity drugs will likely be a major factor.</p>
<p>For 2025/2026, revenues are changed by +1%/+0.4%, and EPS estimates change by +1.9%/-0.7%. No substantial changes to Mounjaro/Zepbound forecasts.</p>
<p>BofA reiterates the Buy rating with a price target of $1,000. &#8220;We continue to like LLY, not &#8220;expensive&#8221; on a PE-to-growth basis, by our math.&#8221;</p>
<p><strong>Price Action:</strong> LLY stock is up 0.59% at $822.84 at the last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/guidance/25/04/44928828/devon-energy-unveils-1-billion-annual-optimization-plan-targets-efficiency-gains-by-2026" target="_blank" rel="noreferrer noopener">Devon Energy Unveils $1 Billion Annual Optimization Plan, Targets Efficiency Gains By 2026</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Analyst Color

Initiation

Analyst Ratings

Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence

<p>On 4/20, while most were lighting up, <strong>Snoop Dogg</strong> dropped a trip—visually speaking.</p>
<p>Directed by <strong>Dave Meyers</strong> and produced by <strong>Psyop</strong> in collaboration with <strong>Temple Caché</strong>, the music video for <strong>&#8220;Last Dance with Mary Jane</strong>&#8220;—Snoop's cannabis-laced reimagining of the <strong>Tom Petty</strong> classic—takes viewers on a mind-bending ride through the rapper's life, inner cities and stoner dreams. The track, from Snoop's &#8220;Missionary&#8221; album, released last year via <strong>Death Row, Aftermath</strong> and <strong>Interscope,</strong> features <strong>Jelly Roll</strong>, cameos by <strong>B-Real</strong>, <strong>Method Man</strong>, <strong>Redman</strong>, <strong>Wiz Khalifa</strong> and even visual nods to <strong>Bob Marley</strong>, <strong>Tupac</strong> and Tom Petty himself.</p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Last Dance with Mary Jane ft. Tom Petty &amp; Jelly Roll (Official Music Video)" width="500" height="281" src="https://www.youtube.com/embed/rseqmSGH7xk?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p>This isn't your typical hip-hop video; it's a genre-smashing blend of handcrafted animation and generative AI, layered across a semi-autobiographical storyline about Snoop's lifelong relationship with cannabis and the justice issues it invokes.</p>
<p>"Being able to partner with Dre, Snoop and Dave to create a visual style that hasn't been done is exactly the type of project we live for," said <strong>Joe Maggiore</strong> of Psyop.</p>
<p>The visuals? Insane. Think 2D, 3D, collage, motion design and surreal AI landscapes. But it's not AI doing the storytelling—every frame was touched by human hands, ensuring emotional nuance and a narrative throughline. "Storytelling requires nuance," said Psyop's <strong>Andrew Linsk</strong>, explaining why AI alone couldn't carry the vision.</p>
<p>The end result is both a love letter to cannabis and a statement on America—its cities, its culture, its contradictions.</p>
<h2 class="wp-block-heading">Meanwhile… Jet Black Roses Go Full Funkadelic</h2>
<p>If Snoop's video is a lucid dream, <strong>Jet Black Roses'</strong> new single is a fever-drenched backyard boogie. Its latest track, <strong>&#8220;Psychoboogie Hoochiecoo,</strong>&#8221; arrives with a brain-melting video by <strong>Steffan Heil</strong> (of Adult Swim fame) and production by <strong>Greg Archilla</strong> (Neil Young, Collective Soul, Matchbox Twenty).</p>
<p>No AI. No autotune. Just brass, groove and sweat.</p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="PsychoBoogieHoochieCoo (Official Music Video)" width="500" height="281" src="https://www.youtube.com/embed/DlQuGfovDEg?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><strong>MusicRow</strong> nailed it: "Funky, horn-punctuated Southern rock with some built-in grease."</p>
<p>The band describes itself as the &#8220;Coolest Dad Rock Band in America,&#8221; but that barely scratches it. Picture the swagger of Little Feat, the freak of Funkadelic and the slink of The Meters—wrapped in Jet Black Roses' Louisiana-born harmonies and storytelling.</p>
<p>It&#8217;s shared stages with <strong>Styx</strong>, <strong>Sammy Hagar</strong> and <strong>Collective Soul</strong>. It&#8217;s not riding genre trends. It&#8217;s playing from the gut—and it shows.</p>
<p>It&#8217;s 2025 is just getting started.</p>
<p><em>Lead image courtesy of Psyop</em></p>


Cannabis

Entertainment

Media

Snoop Dogg's 'Last Dance' Is Cannabis Cinema At Its Weirdest—And There's A Funkadelic 'Dad Rock' Counterpart

SCCO

TECK

VALE

Shares of metals and materials stocks are trading higher following US Treasury Secretary Scott Bessent's reported remarks about trade de-escalation with China. De-escalation with China could reduce demand uncertainty.

<p>Shares of <strong>Tivic Health Systems, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) are soaring Tuesday after the company announced it held senior-level briefings with White House officials and the U.S. Food and Drug Administration (FDA), which resulted in strong interest in potential military and defense <a href="https://www.benzinga.com/pressreleases/25/04/b44920336/tivic-health-reports-white-house-briefing-and-fda-meetings-secured-positive-interest-in-potential-">product candidates</a>.</p>
<p><strong>What To Know: </strong>Tivic disclosed that it presented its therapeutic programs to senior leadership at the White House and FDA  on Thursday. Discussions centered around the company's TLR5 and non-invasive cervical vagus nerve stimulation (ncVNS) programs. </p>
<p>The White House meeting focused on the TLR5 program and its lead product candidate, Entolimod, which is being developed to treat acute radiation syndrome. The briefing addressed the need for better treatment options for radiation exposure and highlighted Entolimod's role in enhancing immune response through the TLR5 pathway, which is part of the body's innate immune system.</p>
<p>The company noted that Entolimod previously received significant development funding from various U.S. government agencies, including BARDA, NASA, the Defense Threat Reduction Agency, the Department of the Army and the Department of Defense. Tivic emphasized the potential for Entolimod to offer advantages over current treatments, such as providing gastrointestinal and hematopoietic protection from radiation in a single dose.</p>
<p>In a separate meeting, Tivic met with senior leadership at the FDA to discuss potential expedited regulatory pathways for both Entolimod and Entolasta, a second-generation TLR5 agonist. </p>
<p>The company also presented its ncVNS program to the FDA, which is targeting a range of inflammatory, cardiac and neurologic conditions. The FDA gave favorable feedback, including potential support for breakthrough device designation upon completion of relevant clinical work.</p>
<p>&#8220;We deeply appreciated the opportunity to discuss the importance of our clinical pipeline in potentially protecting and healing both active and retired military personnel, first responders, as well as U.S. citizens and our allies,&#8221; said Jennifer Ernst, CEO of Tivic Health.</p>
<p>&#8220;While these meetings were informal in nature, we expect to continue these discussions as Entolimod and our ncVNS medical programs progress toward potential FDA approval.&#8221;</p>
<p><strong>TIVC Price Action</strong>: Tivic Health shares traded as high as $13.23 on Tuesday. The stock was up 107.7% at $7.28 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="543" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06-1024x543.png" alt="" class="wp-image-882548" style="width:476px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06-1024x543.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06.png 1496w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44930495/wall-street-rebounds-ahead-of-tesla-earnings-dow-adds-1000-points-bitcoin-hits-91000-whats-driving-markets-tuesday">Wall Street Rebounds Ahead Of Tesla Earnings, Dow Adds 1,000 Points, Bitcoin Hits $91,000: What&#8217;s Driving Markets Tuesday?</a></strong></li>
</ul>
<p><em>Image via Shutterstock.</em></p>


Movers

TIVC

Tivic Health Systems Stock Is On Fire Today: What's Going On?

<p><strong>Invesco QQQ Trust</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), considered a proxy for large-cap growth and tech-dense innovation,  faltered considerably in 2025.</p>
<p><strong>What Happened</strong>: The ETF has had year-to-date losses of 13.44%. While alarming on its own, this number conceals more profound undercurrents within its<a href="https://www.benzinga.com/etfs"> underlying makeup</a>, most notably the fortunes of &#8220;Magnificent Seven&#8221; stocks, which collectively comprise more than 40% of the QQQ.</p>
<p>The decline among these mega-cap growth stars has been swift and, by some accounts, historic. <strong>Roundhill Magnificent Seven ETF</strong> (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>) mirrors this group of stocks and is down over 12% for the past six months.</p>
<p>As investment advisory company Bespoke Investment Group recently<a href="https://www.benzinga.com/25/04/44916598/tariff-pause-fizzles-mag-7-stocks-slide-back-to-pre-pause-lows"><strong> noted, there is more downside risk</strong></a>.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44895562/3-high-risk-etfs-aggressive-retail-investors-cant-stop-buying">3 High-Risk ETFs Aggressive Retail Investors Can&#8217;t Stop Buying</a></strong></p>
<p>A convergence of global macroeconomic headwinds has helped to bring about this weakness. J.P. Morgan Asset Management <a href="https://www.advisorpedia.com/markets/can-mega-cap-tech-stocks-withstand-the-tariff-pressure/">underscores </a>that around 75% of the suppliers to these companies are overseas, many in jurisdictions that are newly subject to fresh tariffs under new U.S. trade policy. </p>
<p>Adding to the squeeze, corporate behemoths and Mag7 members such as <strong>Alphabet </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), <strong>Apple </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and <strong>Microsoft </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) get more than half of their revenues abroad. Consequently, rising trade tensions and supply chain risks continue to be primary risk considerations for investors assessing exposure to QQQ or its underlying tech giants.</p>
<p><strong>Why It Matters</strong>: A wider view presents a more complex picture. According <a href="https://www.advisorpedia.com/markets/can-mega-cap-tech-stocks-withstand-the-tariff-pressure/">to </a>J.P. Morgan&#8217;s <strong>Stephanie Aliaga</strong>, the recent decline has not been caused by a deterioration in underlying fundamentals. </p>
<p>Instead, it is a repricing of risk in the face of heightened uncertainty regarding margins, capital spending, and earnings expectations. This has resulted in significant compression in valuation. </p>
<p>Importantly, the forward price-to-earnings (P/E) multiple for the Magnificent Seven has fallen from around 31x early in the year to about 22x—its lowest price since January 2023, before the then-ongoing artificial intelligence (AI) cycle of investment.</p>
<p>This relative discount may attract long-term investors looking for quality at a better entry point. These companies are at the core of the QQQ portfolio and leading in innovation, especially in AI and cloud computing. Their impact on the overall market, and the QQQ, is still unbroken.</p>
<p>However, near-term prudence is likely to be justified. Trade headwinds are not likely to subside quickly, and more volatility in mega-cap growth can be expected. But for those with the stomach for short-term dislocations, the combination of cheap valuations and continued innovation leadership presents an attractive argument for revisiting QQQ and its Mag 7 exposure.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/etfs/new-etfs/25/04/44933272/rnty-yieldmaxs-bold-new-real-estate-etf-that-builds-income-one-option-at-a-time">RNTY: YieldMax&#8217;s Bold New Real Estate ETF That Builds Income, One Option At A Time</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Specialty ETFs

ETFs

AAPL

GOOGL

MAGS

MSFT

Magnificent Meltdown: QQQ Tanks As Big Tech's Shine Wears Off, But There's A Silver Lining

AIRT

ARRY

AZEK

CARR

Embraer-Empresa Brasileira De Aeronautica

EVTL

HAYW

HLGN

JBHT

LDOS

MATX

NRGV

ODFL

PCAR

SAIA

SHLS

TREX

UHAL

Shares of companies in the broader industrial sector are trading higher following US Treasury Secretary Scott Bessent's reported remarks about trade de-escalation with China.

CMCSA

Xfinity Mobile Reveals New Premium Unlimited Plan That Delivers Gigabit Speeds And Upgraded Features

<p>Old Second Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSBC#NASDAQ">OSBC</a>) will release its quarterly earnings report on Wednesday, 2025-04-23. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Old Second Bancorp to report an <strong>earnings per share</strong> (EPS) of $0.44.</p>
<p>Anticipation surrounds Old Second Bancorp's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS missed by $0.04, leading to a 2.41% drop in the share price on the subsequent day.</p>
<p>Here's a look at Old Second Bancorp's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.48</td>
<td>0.47</td>
<td>0.47</td>
<td>0.46</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.44</td>
<td>0.51</td>
<td>0.46</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>6.0%</td>
<td>-2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745348609_0.png" alt="eps graph" /></p>
<h3>Old Second Bancorp Share Price Analysis</h3>
<p>Shares of Old Second Bancorp were trading at $14.68 as of April 21. Over the last 52-week period, shares are up 4.66%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/OSBC/earnings"><strong>To track all earnings releases for Old Second Bancorp visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

OSBC

An Overview of Old Second Bancorp's Earnings

<p>Kaiser Aluminum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALU#NASDAQ">KALU</a>) will release its quarterly earnings report on Wednesday, 2025-04-23. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Kaiser Aluminum to report an <strong>earnings per share</strong> (EPS) of $0.41.</p>
<p>Anticipation surrounds Kaiser Aluminum's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.08, which was followed by a 4.88% increase in the share price the next day.</p>
<p>Here's a look at Kaiser Aluminum's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.41</td>
<td>0.83</td>
<td>0.91</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.33</td>
<td>0.51</td>
<td>0.65</td>
<td>1.02</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>-0.0%</td>
<td>-16.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745348597_0.png" alt="eps graph" /></p>
<h3>Tracking Kaiser Aluminum's Stock Performance</h3>
<p>Shares of Kaiser Aluminum were trading at $53.65 as of April 21. Over the last 52-week period, shares are down 36.02%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Views on Kaiser Aluminum</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Kaiser Aluminum.</p>
<p>The consensus rating for Kaiser Aluminum is Buy, based on 1 analyst ratings. With an average one-year price target of $74.0, there's a potential 37.93% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Ivanhoe Electric, Nexa Res and Ryerson Holding, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Ivanhoe Electric, with an average 1-year price target of $13.0, suggesting a potential 75.77% downside.</li>
<li>Analysts currently favor an Underperform trajectory for Nexa Res, with an average 1-year price target of $5.33, suggesting a potential 90.07% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Ryerson Holding, with an average 1-year price target of $25.0, suggesting a potential 53.4% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for Ivanhoe Electric, Nexa Res and Ryerson Holding, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaiser Aluminum</td>
<td>Buy</td>
<td>6.06%</td>
<td>$79.50M</td>
<td>1.06%</td>
</tr>
<tr>
<td>Ivanhoe Electric</td>
<td>Outperform</td>
<td>-20.29%</td>
<td>$862K</td>
<td>6.52%</td>
</tr>
<tr>
<td>Nexa Res</td>
<td>Underperform</td>
<td>17.63%</td>
<td>$143.30M</td>
<td>-10.87%</td>
</tr>
<tr>
<td>Ryerson Holding</td>
<td>Neutral</td>
<td>-9.44%</td>
<td>$191.10M</td>
<td>-0.52%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Kaiser Aluminum ranks highest in Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Get to Know Kaiser Aluminum Better</h3>
<p>Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.</p>
<h3>Understanding the Numbers: Kaiser Aluminum's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Kaiser Aluminum showcased positive performance, achieving a revenue growth rate of <strong>6.06%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Kaiser Aluminum's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>0.93%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Kaiser Aluminum's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.06%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Kaiser Aluminum's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.31%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Kaiser Aluminum's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.61</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/KALU/earnings"><strong>To track all earnings releases for Kaiser Aluminum visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


KALU

Preview: Kaiser Aluminum's Earnings

<p>SEI Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) will release its quarterly earnings report on Wednesday, 2025-04-23. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate SEI Inv to report an <strong>earnings per share</strong> (EPS) of $1.14.</p>
<p>SEI Inv bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $0.00 in the last quarter, leading to a 3.7% increase in the share price on the following day.</p>
<p>Here's a look at SEI Inv's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.19</td>
<td>1.07</td>
<td>1.04</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.19</td>
<td>1.19</td>
<td>1.05</td>
<td>0.99</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>5.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745348588_0.png" alt="eps graph" /></p>
<h3>Market Performance of SEI Inv's Stock</h3>
<p>Shares of SEI Inv were trading at $69.67 as of April 21. Over the last 52-week period, shares are up 8.12%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on SEI Inv</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on SEI Inv.</p>
<p>The consensus rating for SEI Inv is Neutral, based on 5 analyst ratings. With an average one-year price target of $84.2, there's a potential 20.86% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Franklin Resources, Blue Owl Capital and Hamilton Lane, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Franklin Resources, with an average 1-year price target of $19.62, suggesting a potential 71.84% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Blue Owl Capital, with an average 1-year price target of $25.6, suggesting a potential 63.26% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Hamilton Lane, with an average 1-year price target of $158.6, suggesting a potential 127.64% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>In the peer analysis summary, key metrics for Franklin Resources, Blue Owl Capital and Hamilton Lane are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEI Inv</td>
<td>Neutral</td>
<td>14.92%</td>
<td>$297.69M</td>
<td>6.76%</td>
</tr>
<tr>
<td>Franklin Resources</td>
<td>Neutral</td>
<td>13.08%</td>
<td>$1.83B</td>
<td>1.19%</td>
</tr>
<tr>
<td>Blue Owl Capital</td>
<td>Outperform</td>
<td>27.80%</td>
<td>$336.88M</td>
<td>1.00%</td>
</tr>
<tr>
<td>Hamilton Lane</td>
<td>Neutral</td>
<td>34.33%</td>
<td>$128.63M</td>
<td>8.44%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>SEI Inv ranks in the middle for Consensus. It is at the bottom for Revenue Growth and Gross Profit, but at the top for Return on Equity among its peers.</p>
<h3>Get to Know SEI Inv Better</h3>
<p>SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $87 billion in assets under management. As of December 2024, SEI (including LSV) manages, administers, or advises about $1.6 trillion in assets.</p>
<h3>SEI Inv: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, SEI Inv showcased positive performance, achieving a revenue growth rate of <strong>14.92%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>27.96%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> SEI Inv's ROE excels beyond industry benchmarks, reaching <strong>6.76%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> SEI Inv's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>5.8%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> SEI Inv's debt-to-equity ratio is below the industry average at <strong>0.01</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/SEIC/earnings"><strong>To track all earnings releases for SEI Inv visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SEIC

Earnings Outlook For SEI Inv

<p>Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) will release its quarterly earnings report on Wednesday, 2025-04-23. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Lithia Motors to report an <strong>earnings per share</strong> (EPS) of $7.75.</p>
<p>The market awaits Lithia Motors's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.55, leading to a 0.26% drop in the share price on the subsequent day.</p>
<p>Here's a look at Lithia Motors's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>7.24</td>
<td>7.59</td>
<td>7.54</td>
<td>7.89</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>7.79</td>
<td>8.21</td>
<td>7.87</td>
<td>6.11</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>0.0%</td>
<td>-2.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745348576_0.png" alt="eps graph" /></p>
<h3>Tracking Lithia Motors's Stock Performance</h3>
<p>Shares of Lithia Motors were trading at $283.82 as of April 21. Over the last 52-week period, shares are up 19.26%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Lithia Motors</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Lithia Motors.</p>
<p>The consensus rating for Lithia Motors is Outperform, based on 7 analyst ratings. With an average one-year price target of $383.0, there's a potential 34.94% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of AutoNation, CarMax and Group 1 Automotive, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for AutoNation, with an average 1-year price target of $194.75, suggesting a potential 31.38% downside.</li>
<li>Analysts currently favor an Outperform trajectory for CarMax, with an average 1-year price target of $90.3, suggesting a potential 68.18% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Group 1 Automotive, with an average 1-year price target of $454.0, suggesting a potential 59.96% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for AutoNation, CarMax and Group 1 Automotive, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lithia Motors</td>
<td>Outperform</td>
<td>19.54%</td>
<td>$1.37B</td>
<td>3.26%</td>
</tr>
<tr>
<td>AutoNation</td>
<td>Neutral</td>
<td>6.59%</td>
<td>$1.24B</td>
<td>7.71%</td>
</tr>
<tr>
<td>CarMax</td>
<td>Outperform</td>
<td>6.69%</td>
<td>$667.89M</td>
<td>1.44%</td>
</tr>
<tr>
<td>Group 1 Automotive</td>
<td>Outperform</td>
<td>23.80%</td>
<td>$879.20M</td>
<td>3.12%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Lithia Motors ranks at the top for Revenue Growth and Gross Profit among its peers. However, it has the lowest Return on Equity. Overall, Lithia Motors is positioned favorably compared to its peers in terms of financial performance metrics.</p>
<h3>Delving into Lithia Motors's Background</h3>
<p>Lithia Motors is a retailer of new and used vehicles and related services. The company offers over 50 brands of vehicles at nearly 500 stores globally across the US, Canada, and UK. The company has expanded largely through the acquisition of dealerships in smaller regional markets but now seeks to grow in any part of the US and we expect more deals over time in the US and, at times, abroad. Annual revenue in 2024 was $36.2 billion and we see over $50 billion possible in a few years. The US was 78% of 2024 revenue and the UK second at 19%, due to the 2024 Pendragon acquisition. In 2024, new vehicle sales were about 49% of total revenue. Lithia was founded in 1946, went public in 1996, and is the largest US auto dealer. It is based in Medford, Oregon.</p>
<h3>Financial Milestones: Lithia Motors's Journey</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Lithia Motors showcased positive performance, achieving a revenue growth rate of <strong>19.54%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Lithia Motors's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>2.36%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Lithia Motors's ROE excels beyond industry benchmarks, reaching <strong>3.26%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Lithia Motors's ROA excels beyond industry benchmarks, reaching <strong>0.93%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>2.08</strong>.</p>
<p><a href="https://www.benzinga.com/quote/LAD/earnings"><strong>To track all earnings releases for Lithia Motors visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of Lithia Motors's Earnings

<p>Taylor Morrison Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMHC#NYSE">TMHC</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-23. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Taylor Morrison Home to report an <strong>earnings per share</strong> (EPS) of $1.81.</p>
<p>Investors in Taylor Morrison Home are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company beat EPS by $0.26, which was followed by a 0.78% drop in the share price the next day.</p>
<p>Here's a look at Taylor Morrison Home's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.38</td>
<td>2.06</td>
<td>1.90</td>
<td>1.60</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.64</td>
<td>2.37</td>
<td>1.97</td>
<td>1.75</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>2.0%</td>
<td>-0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745348567_0.png" alt="eps graph" /></p>
<h3>Taylor Morrison Home Share Price Analysis</h3>
<p>Shares of Taylor Morrison Home were trading at $55.59 as of April 21. Over the last 52-week period, shares are up 3.92%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Taylor Morrison Home</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Taylor Morrison Home.</p>
<p>Analysts have provided Taylor Morrison Home with 4 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $70.25, suggesting a potential 26.37% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Meritage Homes, Champion Homes and Installed Building Prods, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Meritage Homes, with an average 1-year price target of $80.0, suggesting a potential 43.91% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Champion Homes, with an average 1-year price target of $99.67, suggesting a potential 79.29% upside.</li>
<li>Analysts currently favor an Buy trajectory for Installed Building Prods, with an average 1-year price target of $207.5, suggesting a potential 273.27% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Meritage Homes, Champion Homes and Installed Building Prods are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taylor Morrison Home</td>
<td>Outperform</td>
<td>16.67%</td>
<td>$564.01M</td>
<td>4.19%</td>
</tr>
<tr>
<td>Meritage Homes</td>
<td>Neutral</td>
<td>-2.31%</td>
<td>$380.31M</td>
<td>3.39%</td>
</tr>
<tr>
<td>Champion Homes</td>
<td>Neutral</td>
<td>15.28%</td>
<td>$181.02M</td>
<td>4.07%</td>
</tr>
<tr>
<td>Installed Building Prods</td>
<td>Buy</td>
<td>4.09%</td>
<td>$251.80M</td>
<td>9.41%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Taylor Morrison Home ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Consensus rating and Return on Equity.</p>
<h3>All You Need to Know About Taylor Morrison Home</h3>
<p>Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.</p>
<h3>Unraveling the Financial Story of Taylor Morrison Home</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Taylor Morrison Home displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>16.67%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>10.29%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Taylor Morrison Home's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>4.19%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.61%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Taylor Morrison Home's debt-to-equity ratio is below the industry average. With a ratio of <b>0.37</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/TMHC/earnings"><strong>To track all earnings releases for Taylor Morrison Home visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TMHC

Taylor Morrison Home Earnings Preview

<p>Financial giants have made a conspicuous bullish move on T-Mobile US. Our analysis of options history for T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) revealed 10 unusual trades.</p>
<p>Delving into the details, we found 30% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $208,469, and 5 were calls, valued at $191,586.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $230.0 to $310.0 for T-Mobile US during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for T-Mobile US's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of T-Mobile US's whale trades within a strike price range from $230.0 to $310.0 in the last 30 days. </p>
<h3>T-Mobile US Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745348565_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TMUS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/25/25</td>
<td>$6.7</td>
<td>$6.05</td>
<td>$6.7</td>
<td>$257.50</td>
<td>$53.6K</td>
<td>25</td>
<td align="right">178</td>
</tr>
<tr>
<td>TMUS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/25/25</td>
<td>$7.0</td>
<td>$5.75</td>
<td>$6.4</td>
<td>$257.50</td>
<td>$51.2K</td>
<td>25</td>
<td align="right">83</td>
</tr>
<tr>
<td>TMUS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$6.15</td>
<td>$5.9</td>
<td>$6.14</td>
<td>$250.00</td>
<td>$47.9K</td>
<td>2.2K</td>
<td align="right">80</td>
</tr>
<tr>
<td>TMUS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/25/25</td>
<td>$4.45</td>
<td>$4.1</td>
<td>$4.42</td>
<td>$252.50</td>
<td>$46.6K</td>
<td>34</td>
<td align="right">272</td>
</tr>
<tr>
<td>TMUS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/25/25</td>
<td>$4.45</td>
<td>$4.15</td>
<td>$4.33</td>
<td>$252.50</td>
<td>$41.0K</td>
<td>34</td>
<td align="right">517</td>
</tr>
</tbody>
</table>
</p>
<h3>About T-Mobile US</h3>
<p>Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, and that firm merged with Sprint in 2020, creating the second-largest wireless carrier in the us. T-Mobile now serves 77 million postpaid and 21 million prepaid phone customers, equal to around 30% of the us retail wireless market. The firm entered the fixed-wireless broadband market aggressively in 2021 and now serves more than 5 million residential and business customers. In addition, T-Mobile provides wholesale services to resellers.</p>
<p>Having examined the options trading patterns of T-Mobile US, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of T-Mobile US</h3>
<ul>
<li>Trading volume stands at 2,764,506, with TMUS's price up by 1.31%, positioned at $256.81.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 2 days.</li>
</ul>
<h3>What Analysts Are Saying About T-Mobile US</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $275.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Benchmark downgraded its rating to Buy, setting a price target of $275. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for T-Mobile US with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

TMUS

Smart Money Is Betting Big In TMUS Options

<p>Deep-pocketed investors have adopted a bullish approach towards Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PLTR usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 97 extraordinary options activities for Palantir Technologies. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 53% leaning bullish and 37% bearish. Among these notable options, 37 are puts, totaling $3,046,402, and 60 are calls, amounting to $3,884,242.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $155.0 for Palantir Technologies over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Palantir Technologies's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Palantir Technologies's significant trades, within a strike price range of $30.0 to $155.0, over the past month.</p>
<h3>Palantir Technologies Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745348560_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/23/25</td>
<td>$0.97</td>
<td>$0.89</td>
<td>$0.97</td>
<td>$60.00</td>
<td>$776.0K</td>
<td>20.7K</td>
<td>10.1K</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.45</td>
<td>$61.8</td>
<td>$62.2</td>
<td>$35.00</td>
<td>$186.6K</td>
<td>9.7K</td>
<td>50</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$2.96</td>
<td>$2.92</td>
<td>$2.92</td>
<td>$65.00</td>
<td>$139.9K</td>
<td>5.8K</td>
<td>495</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$4.9</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$110.00</td>
<td>$139.2K</td>
<td>634</td>
<td>633</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$14.6</td>
<td>$14.5</td>
<td>$14.6</td>
<td>$97.50</td>
<td>$127.0K</td>
<td>1.1K</td>
<td>179</td>
</tr>
</tbody>
</table>
</p>
<h3>About Palantir Technologies</h3>
<p>Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.</p>
<p>In light of the recent options history for Palantir Technologies, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Palantir Technologies's Current Market Status</h3>
<ul>
<li>Trading volume stands at 73,511,636, with PLTR's price up by 3.98%, positioned at $94.41.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 13 days.</li>
</ul>
<h3>What Analysts Are Saying About Palantir Technologies</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $95.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Palantir Technologies, which currently sits at a price target of $90.<br />
&#x2A; Maintaining their stance, an analyst from DA Davidson continues to hold a Neutral rating for Palantir Technologies, targeting a price of $100. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Palantir Technologies with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


PLTR

Market Whales and Their Recent Bets on PLTR Options

<p><strong>Prosperity Bancshares</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PB#NYSE">PB</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-23. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Prosperity Bancshares will report an <strong>earnings per share</strong> (EPS) of $1.35. </p>
<p>Anticipation surrounds Prosperity Bancshares's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.04 in the last quarter, leading to a 1.08% increase in the share price on the following day.</p>
<p>Here's a look at Prosperity Bancshares's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.33</td>
<td>1.31</td>
<td>1.18</td>
<td>1.16</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.37</td>
<td>1.34</td>
<td>1.22</td>
<td>1.18</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>0.0%</td>
<td>2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745348558_0.png" alt="eps graph" /></p>
<h3>Performance of Prosperity Bancshares Shares</h3>
<p>Shares of Prosperity Bancshares were trading at $65.53 as of April 21. Over the last 52-week period, shares are up 3.19%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PB/earnings"><strong>To track all earnings releases for Prosperity Bancshares visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What's Next: Prosperity Bancshares's Earnings Preview

<p>Financial giants have made a conspicuous bearish move on Palo Alto Networks. Our analysis of options history for Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) revealed 34 unusual trades.</p>
<p>Delving into the details, we found 26% of traders were bullish, while 58% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $963,653, and 22 were calls, valued at $4,345,075.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $80.0 and $190.0 for Palo Alto Networks, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Palo Alto Networks stands at 1214.7, with a total volume reaching 18,644.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Palo Alto Networks, situated within the strike price corridor from $80.0 to $190.0, throughout the last 30 days.</p>
<h3>Palo Alto Networks Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745348554_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$4.5</td>
<td>$4.35</td>
<td>$4.5</td>
<td>$190.00</td>
<td>$1.0M</td>
<td>773</td>
<td>2.4K</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$29.6</td>
<td>$29.0</td>
<td>$29.0</td>
<td>$170.00</td>
<td>$812.0K</td>
<td>2.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$29.0</td>
<td>$28.0</td>
<td>$29.0</td>
<td>$170.00</td>
<td>$718.3K</td>
<td>2.1K</td>
<td>578</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$29.2</td>
<td>$29.0</td>
<td>$29.0</td>
<td>$170.00</td>
<td>$385.7K</td>
<td>2.1K</td>
<td>722</td>
</tr>
<tr>
<td>PANW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.05</td>
<td>$3.95</td>
<td>$4.05</td>
<td>$135.00</td>
<td>$384.7K</td>
<td>89</td>
<td>952</td>
</tr>
</tbody>
</table>
</p>
<h3>About Palo Alto Networks</h3>
<p>Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.</p>
<p>Having examined the options trading patterns of Palo Alto Networks, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Palo Alto Networks</h3>
<ul>
<li>Trading volume stands at 2,207,563, with PANW's price up by 2.34%, positioned at $163.79.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<h3>Expert Opinions on Palo Alto Networks</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $195.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from HSBC has elevated its stance to Hold, setting a new price target at $156.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Palo Alto Networks, which currently sits at a price target of $205.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on Palo Alto Networks, maintaining a target price of $205.<br />
&#x2A; An analyst from Keybanc persists with their Overweight rating on Palo Alto Networks, maintaining a target price of $205.<br />
&#x2A; An analyst from Stephens &amp; Co. has revised its rating downward to Equal-Weight, adjusting the price target to $205. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Palo Alto Networks, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


PANW

Decoding Palo Alto Networks's Options Activity: What's the Big Picture?

<p>GATX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATX#NYSE">GATX</a>) will release its quarterly earnings report on Wednesday, 2025-04-23. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate GATX to report an <strong>earnings per share</strong> (EPS) of $2.09.</p>
<p>GATX bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.22, leading to a 3.69% increase in the share price the following trading session.</p>
<p>Here's a look at GATX's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.71</td>
<td>1.85</td>
<td>1.77</td>
<td>1.76</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.93</td>
<td>2.50</td>
<td>1.43</td>
<td>2.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745348548_0.png" alt="eps graph" /></p>
<h3>GATX Share Price Analysis</h3>
<p>Shares of GATX were trading at $145.62 as of April 21. Over the last 52-week period, shares are up 17.29%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GATX/earnings"><strong>To track all earnings releases for GATX visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GATX

A Peek at GATX's Future Earnings

Comments

Themes US Cash Flow Champions ETF

Actualités

Dernières nouvelles pour Themes US Cash Flow Champions ETF (NASDAQ:LGCF)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL